HRXG-K-1939 / Fudan University - LARVOL DELTA

A pilot study of a personalized cancer vaccine in combination with immune checkpoint inhibitor in advanced pancreatic cancer. (ASCO 2026) - P1 | "HRXG-K-1939 combination with ICI demonstrated a manageable safety profile, along with encouraging signs of efficacy and immunogenicity in this study. These findings support the further development of personalized neoantigen vaccines in advanced pancreatic cancer."

Checkpoint inhibition • Clinical • Combination therapy • IO biomarker • Metastases • Oncology • Pancreatic Cancer • Solid Tumor

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Fudan University

Metastases • New P1 trial • Oncology • Solid Tumor • IL10 • IL2 • IL6